317 related articles for article (PubMed ID: 26395890)
1. [Liquid biopsy analysis using cell-free DNA (cfDNA): Opportunities and limitations].
Dahl E; Kloten V
Pathologe; 2015 Nov; 36(6):572-8. PubMed ID: 26395890
[TBL] [Abstract][Full Text] [Related]
2. Pathologists and liquid biopsies: to be or not to be?
Hofman P; Popper HH
Virchows Arch; 2016 Dec; 469(6):601-609. PubMed ID: 27553354
[TBL] [Abstract][Full Text] [Related]
3. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
[TBL] [Abstract][Full Text] [Related]
4. EGFR mutations in lung cancer: from tissue testing to liquid biopsy.
Fenizia F; De Luca A; Pasquale R; Sacco A; Forgione L; Lambiase M; Iannaccone A; Chicchinelli N; Franco R; Rossi A; Morabito A; Rocco G; Piccirillo MC; Normanno N
Future Oncol; 2015; 11(11):1611-23. PubMed ID: 26043215
[TBL] [Abstract][Full Text] [Related]
5. [Cytological material for molecular pathology].
Heukamp LC; Bubendorf L
Pathologe; 2015 Nov; 36(6):566-71. PubMed ID: 26483251
[TBL] [Abstract][Full Text] [Related]
6. [Chances and risks of blood-based molecular pathological analysis of circulating tumor cells (CTC) and cell-free DNA (cfDNA) in personalized cancer therapy: positional paper from the study group on liquid biopsy of the working group for molecular pathology in the German Society of Pathology (DGP)].
Dahl E; Jung A; Fassunke J; Hummel M; Penzel R; Dietmaier W; Laßmann S
Pathologe; 2015 Feb; 36(1):92-7. PubMed ID: 25533324
[No Abstract] [Full Text] [Related]
7. Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid.
Park S; Hur JY; Lee KY; Lee JC; Rho JK; Shin SH; Choi CM
Clin Chem Lab Med; 2017 Aug; 55(10):1489-1495. PubMed ID: 28195541
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor mutation status in cell-free DNA supernatant of bronchial washings and brushings.
Kawahara A; Fukumitsu C; Taira T; Abe H; Takase Y; Murata K; Yamaguchi T; Azuma K; Ishii H; Takamori S; Akiba J; Hoshino T; Kage M
Cancer Cytopathol; 2015 Oct; 123(10):620-8. PubMed ID: 26235264
[TBL] [Abstract][Full Text] [Related]
9. [Liquid Biopsy: Detection of Molecular Markers for Treatment Decisions in Lung Cancer].
Brückl WM; Wirtz RM; Bertsch T; Ficker JH; Jung A
Pneumologie; 2017 Mar; 71(3):151-163. PubMed ID: 28196386
[TBL] [Abstract][Full Text] [Related]
10. Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer.
Bennett CW; Berchem G; Kim YJ; El-Khoury V
Oncotarget; 2016 Oct; 7(43):71013-71035. PubMed ID: 27589834
[TBL] [Abstract][Full Text] [Related]
11. Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).
Finotti A; Allegretti M; Gasparello J; Giacomini P; Spandidos DA; Spoto G; Gambari R
Int J Oncol; 2018 Oct; 53(4):1395-1434. PubMed ID: 30085333
[TBL] [Abstract][Full Text] [Related]
12. The potential of liquid biopsies.
Buder A; Tomuta C; Filipits M
Curr Opin Oncol; 2016 Mar; 28(2):130-4. PubMed ID: 26730486
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
[TBL] [Abstract][Full Text] [Related]
14. Liquid biopsy approaches for pleural effusion in lung cancer patients.
Baburaj G; Damerla RR; Udupa KS; Parida P; Munisamy M; Kolesar J; Rao M
Mol Biol Rep; 2020 Oct; 47(10):8179-8187. PubMed ID: 33029702
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathology in real time.
Ryška A
Cancer Metastasis Rev; 2016 Mar; 35(1):129-40. PubMed ID: 26931654
[TBL] [Abstract][Full Text] [Related]
16. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
[TBL] [Abstract][Full Text] [Related]
17. [Innovations in personalized medicine : Molecular characterization of liquid biopsy-fake or fact?].
Theil G; Fornara P
Urologe A; 2018 Sep; 57(9):1069-1074. PubMed ID: 29971453
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of cell-free circulating tumor DNA testing for lung cancer.
Santarpia M; Karachaliou N; González-Cao M; Altavilla G; Giovannetti E; Rosell R
Biomark Med; 2016; 10(4):417-30. PubMed ID: 26974841
[TBL] [Abstract][Full Text] [Related]
19. [Application of Liquid Biopsy for Lung Cancer Treatment.].
Mori S; Yatabe Y
Rinsho Byori; 2016 May; 64(4):407-411. PubMed ID: 29182807
[TBL] [Abstract][Full Text] [Related]
20. [Liquid biopsy in tumor diagnostics : Applications, perspectives, and limitations of the "cancer liquidome"].
Lehmann U; Bartels S
Pathologe; 2019 May; 40(3):250-255. PubMed ID: 31049676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
